
样式: 排序: IF: - GO 导出 标记为已读
-
Occult Right Ventricular Dysfunction and Right Ventricular-Vascular Uncoupling in Left Ventricular Assist Device Recipients J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-28 Paul J III Scheel, Ilton M Cubero Salazar, Samuel Friedman, Leora Haber, Monica Mukherjee, Matthew Kauffman, Alexandra Weller, Fatimah Alkhunaizi, Nisha A Gilotra, Kavita Sharma, Ahmet Kilic, Paul M Hassoun, William K Cornwell, Ryan J Tedford, Steven Hsu
Background Current assessments remain insensitive for detecting right heart failure post left ventricular assist device (LVAD). Sensitive pressure-volume loop assessments of right ventricle (RV) contractility may improve our appreciation of post-LVAD RV dysfunction. Methods Thirteen LVAD patients and 20 reference (non-LVAD) subjects underwent comparison of echocardiographic, right heart cath hemodynamic
-
Next Generation Device Interrogation for the HeartMate 3 J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-25 Jonathan Grinstein, Luke A. Ziegler, Palak Shah
Abstract not available
-
Iron Deficiency and Anemia in Pediatric Dilated Cardiomyopathy are Associated with Clinical, Biochemical and Hematological Markers of Severe Disease and Adverse Outcomes J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-25 Jack C. Luxford, Charlene E. Casey, Phil A. Roberts, Claire A. Irving
Background There is limited evidence regarding the prevalence and impact of iron deficiency (ID) in children with dilated cardiomyopathy (DCM). Methods Retrospective single-centre review of all children between 2010-2020 with a diagnosis of DCM and complete iron studies. ID was defined as ≥ 2 of ferritin < 20 μg/L, iron < 9 μmol/L, transferrin > 3 g/L or transferrin saturation < 15%. Clinical and laboratory
-
Best practices for statistical analysis of pretransplant medical urgency J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-24 Grace R. Lyden, Daniel Y. Johnson, Jon J. Snyder, Jessica R. Golbus, William F. Parker
One of the most important goals of the organ allocation system is to prioritize candidates by their relative medical urgency. Ensuring that this aim is achieved translates to a challenging biostatistical problem. Motivated by a recent example in exception priority listings for heart transplant candidates, we developed a set of best practices for comparing medical urgency between groups of waitlisted
-
Long-term effects of pulmonary endarterectomy on pulmonary hemodynamics, cardiac function and exercise capacity in chronic thromboembolic pulmonary hypertension J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-23 Azar Kianzad, Andrea Baccelli, Natalia J. Braams, Stine Andersen, Jessie van Wezenbeek, Jeroen N. Wessels, Lucas R. Celant, Anna E. Vos, Rachel Davies, Francesco Lo Giudice, Gulammehdi Haji, Rocco F. Rinaldo, Beatrice Vigo, Deepa Gopalan, Petr Symersky, Jacobus A. Winkelman, Anco Boonstra, Esther J. Nossent, J. Tim Marcus, Anton Vonk Noordegraaf, Harm Jan Bogaard
-
The Utility of the Stanford Integrative Psychosocial Assessment for Transplant (SIPAT) in Predicting Outcomes Before and After Lung Transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-22 Glen P Westall, Hayley Barnes, Kovi Levin, Nicole Gaffney, Jane Harris, Otto Martinez, Christie Emsley, Louise Fuller, Bronwyn Levvey, Greg I Snell, Toby Winton-Brown
Background Optimizing donor use and achieving maximal survival following lung transplantation (LTx) requires a pre-transplant assessment that identifies clinical, physiological and psychosocial patient factors associated with both poor and optimal post-LTx survival. We examined the utility of a psychosocial tool, the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) to identify patient
-
Corrigendum to ‘Center volume effect on acute cellular rejection and outcomes in pediatric lung transplant recipients’ [J Heart Lung Transplant 2023; 42(8):1030–1039] J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-18 Amalia Guzman-Gomez, Hosam F. Ahmed, Alia Dani, Farhan Zafar, David G. Lehenbauer, Andrew S. Potter, David L.S. Morales, Assem G. Ziady, Don Hayes
Abstract not available
-
Derivation and validation of a non-invasive prediction tool to identify pulmonary hypertension in patients with IPF: evolution of the model FORD J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-17 Steven D. Nathan, Abhimanyu Chandel, Ya Wang, Jiawei Xu, Lixin Shao, Timothy R. Watkins, Jack Diviney, Christopher S. King, Ling Han
Rationale The administration of inhaled prostanoids to patients with pulmonary hypertension (PH) related to idiopathic pulmonary fibrosis (IPF) and other fibrotic interstitial lung diseases improves functional outcomes. Selection of patients with IPF at high risk for concomitant PH to undergo right heart catheterization (RHC) remains challenging. Objective To develop a simple clinical prediction tool
-
Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejection J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-14 Michael B. Keller, Xin Tian, Moon Kyoo Jang, Rohan Meda, Ananth Charya, Deniz Ozisik, Gerald J. Berry, Charles C. Marboe, Hyesik Kong, Ileana L. Ponor, Shambhu Aryal, Jonathan B. Orens, Pali D. Shah, Steven D. Nathan, Sean Agbor-Enoh
Background The association between Organizing Pneumonia (OP) after lung transplantation with the development of acute rejection (AR) remains undefined. In addition, molecular allograft injury, as measured by donor-derived cell-free DNA (dd-cfDNA), during episodes of OP and its relationship to episodes of AR, chronic lung allograft dysfunction (CLAD) or death is unknown. Methods This multicenter, prospective
-
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-14 Davide Stolfo, Matteo Pagnesi, Mauro Chiarito, Luca Baldetti, Marco Merlo, Carlo Mario Lombardi, Ferdinando Loiacono, Alberto Maria Cappelletti, Stefano Contessi, Daniele Cocianni, Maria Perotto, Marianna Adamo, Filippo Calì, Riccardo Maria Inciardi, Daniela Tomasoni, Marta Maccallini, Alessandro Villaschi, Gaia Gasparini, Marco Montella, Giuseppe Barone, Gianfranco Sinagra
-
Outcomes following Lung Transplantation for American Indians/Alaska Natives in the United States J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-14 Michelle N. Bremer, Garrick J. Gama, Sarah Golts, Christine M. Lin, Aarya Kafi, Gordon Yung, Eugene Golts, Kamyar Afshar
Limited data is available for American Indians /Alaska Natives (AI/AN) undergoing lung transplant. The goal of our study was to assess outcomes for AI/AN lung transplant recipients (LTR). A retrospective review of data from the Organ Procurement and Transplant Network was performed comparing AI/AN (n=88) and Caucasian (n=22,767) LTRs between May 4, 2005 and October 31, 2019. AI/AN LTRs had worse functional
-
-
Validation of the Minnesota Pectoralis Risk Score to Predict Mortality in the HeartMate 3 Population J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-11 Chesney B Siems, Ziyu Ji, Zeina Jedeon, Jessica Schultz, Levi Teigen, Tadashi Allen, Ranjit John, Jerry D Estep, Maria Masotti, Tamas Alexy, Forum Kamdar, Val Maharaj, Marc Pritzker, Daniel Garry, Andrew Shaffer, Rebecca Cogswell
Purpose The Minnesota Pectoralis Risk Score (MPRS) utilizes CT-quantified thoracic muscle and clinical variables to predict survival after left ventricular assist device (LVAD) implantation. The model has not been prospectively tested in HeartMate 3 recipients. Methods A single-center HeartMate 3 cohort from July 2016-July 2021 (n=108) was utilized for this analysis. Cohort subjects with complete co-variates
-
-
Information for Readers J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-09
Abstract not available
-
CorrigendumCorrigendum to ‘The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support’ [The Journal of Heart and Lung Transplantation, Volume 42, Issue 4, April 2023, Pages e1-e64 J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-09 Alexander M. Bernhardt, Hannah Copeland, Anita Deswal, Jason Gluck, Michael M. Givertz
Abstract not available
-
Hyperammonemia Syndrome in Lung Transplant Recipients – a Survey on Current Clinical Practice J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-10 Laura N. Walti, Lorenzo del Sorbo, Shahid Husain
Abstract not available
-
Waitlist and Transplant Outcomes in Heart Transplant Candidates Bridged with Temporary Endovascular Right Ventricular Assist Devices J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-10 Jennie H. Kwon, Savannah H. Skidmore, Krishna Bhandari, Anthony P. Carnicelli, Jeffrey P. Yourshaw, Khaled Shorbaji, Arman Kilic
Background Advances in mechanical circulatory support and changes in allocation policy have shifted waitlisting practices for heart transplantation (HT) in the US. This analysis reports waitlist and transplant outcomes among HT candidates bridged with temporary endovascular right ventricular assist devices (tRVADs). Methods Patients awaiting HT from 2008-2022 in the UNOS registry were grouped by presence
-
18F-FDG PET/CT in left ventricular assist device infections: in-depth characterization and clinical implications J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-10 Ana Devesa, Eman Rashed, Noah Moss, Philip M. Robson, Renata Pyzik, Julie Roldan, Sarah Taimur, Meenakshi M Rana, Kimberly Ashley, Anna Young, Gopi Patel, Kiran Mahmoud, Sumeet S. Mitter, Anuradha Lala, Maya Barghash, Arieh Fox, Ashish Correa, Preethi Pirlamarla, Johanna Contreras, Aditya Parikh, Maria Giovanna Trivieri
-
Disturbance in bodily experience following ventricular assist device implantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-11-03 Fabian Richter, Hannah Spielmann, Sandra Semmig-Koenze, Christine Spitz-Köberich, Christoph Knosalla, Christiane Kugler, Katharina Tigges-Limmer, Wolfgang Albert
Background Disturbance in bodily experience (BE) is a potential adverse consequence of ventricular assist device (VAD) implantation. The concept BE encompasses all cognitive and affective processes related to the subjective experience of one’s own body. Methods A cross-sectional, multi-center study was performed, involving 365 VAD patients (85 % male; time post-implant: 3 – 36 months). Patients completed
-
Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times – results of the Australian and New Zealand trial J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-31 David C McGiffin, Christina E Kure, Peter S Macdonald, Paul C Jansz, Sam Emmanuel, Silvana F Marasco, Atsuo Doi, Chris Merry, Robert Larbalestier, Amit Shah, Agneta Geldenhuys, Amul K Sibal, Cara A Wasywich, Jacob Mathew, Eldho Paul, Caitlin Cheshire, Angeline Leet, James L Hare, Sandra Graham, John F Fraser, David M Kaye
Background Cold static storage (CSS) preservation of donor hearts for periods longer than 4 hours increases the risk of primary graft dysfunction (PGD). The aim of the study was to determine if hypothermic oxygenated perfusion (HOPE) could safely prolong the preservation time of donor hearts. Methods We conducted a non-randomised, single arm, multi-center investigation of the effect of HOPE using the
-
Ambulatory Seven-Day Mechanical Circulatory Support in Sheep Model of Pulmonary Hypertension and Right Heart Failure J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-29 Rei Ukita, Yatrik J Patel, W Kelly Wu, Sean A Francois, Michael Cortelli, Carl A Johnson, Nancy Cardwell, Jennifer R Talackine, John W Stokes, William Grogan, Meredith Mentz, Kaitlyn M Tracy, Timothy R Harris, William Tucker, Elizabeth Simonds, Caitlin T Demarest, Keith E Cook, David J Skoog, Erika B. Rosenzweig, Matthew Bacchetta
Objective Right heart failure is the major cause of death in pulmonary hypertension. Lung transplantation is the only long-term treatment option for patients who fail medical therapy. Due to the scarcity of donor lungs, there is a critical need to develop durable mechanical support for the failing right heart. A major design goal for durable support is to reduce the size and complexity of devices to
-
The Impact of the COVID-19 Pandemic on Drug Overdoses in the United States and the Effect on Cardiac Transplant Volume and Survival J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-27 Katherine G. Phillips, Les James, Marie Rabadi, Eugene A. Grossi, Deane Smith, Aubrey C. Galloway, Nader Moazami
Objectives Drug overdose (DO) deaths rose to unprecedented levels during the COVID-19 pandemic. This study examines the impact of COVID-19 on the availability of cardiac allografts from DO donors and the implications of DO donor use on recipient survival. Methods Heart transplants reported to the United Network for Organ Sharing (UNOS) from January 2017-November 2019 (“pre-COVID”) and March 2020-June
-
SOCIOECONOMIC DEPRIVATION AND HEART TRANSPLANTATION: A CALL FOR PROGRESS IN THE U.S. AND EUROPE J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-24 Alessandra Agnese GROSSI, Luciano POTENA, Joseph W. ROSSANO, Khadijah BREATHETT
Abstract not available
-
SCHOOL-AGE AND ADOLESCENT HEART FAILURE FOLLOWING THE NORWOOD PROCEDURE,, J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-20 William T. Mahle, Rohali Keesari, Felicia Trachtenberg, Jane W. Newburger, Heang Lim, Jonathan Edelson, Aamir Jeewa, Ashwin Lal, Steven J. Kindel, Kristin M. Burns, Sean Lang, Jessica Bainton, Michael Carboni, Chet R. Villa, Marc Richmond, Heather Henderson, Jondavid Menteer, Christian Pizarro, Caren S. Goldberg
Background Heart failure results in significant morbidity and mortality for young children with hypoplastic left heart syndrome (HLHS) following the Norwood procedure. The trajectory in later childhood is not well described. Methods We studied the outcome into adolescence of participants enrolled in the Single Ventricle Reconstruction (SVR) trial who underwent the Fontan procedure or survived to 6
-
Lung Transplantation from Hepatitis C+ Donor Lungs: Reassuring Mid-Term Outcomes J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-20 Samuel T. Kim, Yu Xia, Jonathan K. Ho, Erin Lowery, Daniel P. McCarthy, Abbas Ardehali
Objective The development of modern antiviral therapy for hepatitis C virus (HCV) has allowed for the transplantation of HCV nucleic acid amplification testing positive (NAT+) donor lungs with acceptable short-term outcomes. We sought to evaluate trends and mid-term outcomes of lung transplant recipients of HCV NAT+ donor allografts. Methods All adults undergoing isolated lung transplantation in the
-
Donation After Circulatory Death Significantly Reduces Waitlist Times While Not Changing Post-Heart Transplant Outcomes: A United Network for Organ Sharing Analysis J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-18 Hosam F. Ahmed, Kevin Kulshrestha, John T. Kennedy, Amalia Gomez-Guzman, Jason W. Greenberg, Md Monir Hossain, Yin Zhang, David D’Alessandro, Ranjit John, Nader Moazami, Clifford Chin, Awais Ashfaq, Farhan Zafar, David L S Morales
Objective Recently, several centers in the US have begun performing donation after circulatory death (DCD) heart transplants (HT) in adults. We sought to characterize the recent use of DCD HT, waitlist-time, and outcomes compared to donation after brain death (DBD). Methods Using the UNOS database, 10,402 adult (>18yo) HT recipients from January 2019-June 2022 were identified: 425(4%) were DCD and
-
ISHLT Transplant Registry relaunch: A call to action: Notes from the ISHLT Transplant Registry Director J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-18 Rebecca Cogswell
Abstract not available
-
The Evolving Impact of the COVID-19 Pandemic on Lung Transplant Recipients: A Single-Center Experience J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-17 Devika Sindu, Deepika Razia, Curt Bay, Josna Padiyar, Katherine Grief, Bhuvin Buddhdev, Ashwini Arjuna, Hesham Abdelrazek, Hesham Mohamed, Kendra McAnally, Ashraf Omar, Rajat Walia, Lara Schaheen, Sofya Tokman
Background Lung transplant recipients (LTRs) are at increased risk of COVID-19-related morbidity and mortality; however, the disease severity has changed as SARS-CoV-2 variants have mutated. We compared COVID-19-related clinical outcomes in LTRs at different stages of the pandemic. We also identified risk factors for the development of severe COVID-19 independent of the dominant SARS-CoV-2 variant
-
In vivo lung perfusion for prompt recovery from primary graft dysfunction after lung transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-16 Kei Matsubara, Kentaroh Miyoshi, Shinichi Kawana, Yujiro Kubo, Dai Shimizu, Yasuaki Tomioka, Toshio Shiotani, Haruchika Yamamoto, Shin Tanaka, Takeshi Kurosaki, Toshiaki Ohara, Mikio Okazaki, Seiichiro Sugimoto, Akihiro Matsukawa, Shinichi Toyooka
Background No proven treatment after the development of primary graft dysfunction (PGD) is currently available. Here we established a novel strategy of in vivo lung perfusion (IVLP) for the treatment of PGD. IVLP involves the application of an in vivo isolated perfusion circuit to an implanted lung. This study aimed to explore the effectiveness of IVLP versus conventional post-lung transplant (LTx)
-
A surgical mouse model of neonatal right ventricular outflow tract obstruction by pulmonary artery banding J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-14 Debao Li, Haifa Hong, Minghui Li, Xiuxia Xu, Shoubao Wang, Yingying Xiao, Sixie Zheng, Zheng Wang, Yi Yan, Hao Chen, Chunxia Zhou, Hao Zhang, Qi Sun, Lincai Ye
-
Longitudinal Analysis Left Ventricular Chamber Responses Under Durable LVAD Support J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-14 Aaron Gunawan, Desiree Robson, Rohan J Krishnaswamy, Anju Ramanayake, Katherine Kearney, Kavitha Muthiah, Pankaj Jain, Audrey Adji, Christopher S Hayward
Background Left ventricular assist device (LVAD) support offers remodelling potential in some patients. Our goal was to use non-invasively derived pressure-volume (PV) loops to understand the effect of demographic and device variables on serial changes in cardiac function under pump support. Methods Thirty-two consecutive Medtronic HVAD patients (mean 55.9±12.3 years, 81.3% male) were prospectively
-
Detecting and Managing Cardiac Allograft Vasculopathy Within the Transition from Pediatric to Adult Heart Transplantation Care: Lighting the Pathway Ahead J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-13 Amanda R Vest, Kevin P Daly
Abstract not available
-
The devil is in the details: a commentary on registry analyses of characteristics and outcomes of lung transplants using ex-vivo lung perfusion J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-10 Sandra Lindstedt, Anna Niroomand, Gregory Snell
Abstract not available
-
-
-
Information for Readers J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-11
Abstract not available
-
THE IMPACT OF INTRA-OPERATIVE THERAPEUTIC PLASMA EXCHANGE ON BLEEDING IN LUNG TRANSPLANTATION J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-07 Sahar A. Saddoughi, Tereza Martinu, Christopher Patriquin, David Barth, Ella Huszti, Rasheed Ghany, Kathryn Tinckam, Karen McRae, Lianne G. Singer, Shaf Keshavjee, Marcelo Cypel, Meghan Aversa
Purpose Our program uses a desensitization protocol that includes intraoperative therapeutic plasma exchange (iTPE) for crossmatch positive lung transplants, which improves access to lung transplant for sensitized candidates while mitigating immunologic risk. Although we have reported excellent outcomes for sensitized patients with the use of this protocol, concern for peri-operative bleeding appears
-
Cytomegalovirus Infection is Associated with Impaired Myocardial Flow Reserve After Heart Transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-07 Keerthi T. Gondi, Daniel R. Kaul, Kevin S. Gregg, Jessica R. Golbus, Keith D. Aaronson, Venkatesh L. Murthy, Matthew C. Konerman
Background Cardiac allograft vasculopathy (CAV) limits long-term survival after heart transplantation (HT). This study evaluates the relationship between clinically significant CMV infection (CS-CMVi) and CAV using cardiac positron emission tomography (PET). Methods We retrospectively evaluated HT patients from 2005-2019 who underwent cardiac PET for CAV evaluation. Multivariable linear and logistic
-
ASSESSING THE ROLE OF PHOSPHORYLATED S6 RIBOSOMAL PROTEIN IN THE PATHOLOGICAL DIAGNOSIS OF PULMONARY ANTIBODY-MEDIATED REJECTION J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-06 Francesca Lunardi, Luca Vedovelli, Federica Pezzuto, Jerome Le Pavec, Peter Dorfmuller, Marina Ivanovic, Tahuanty Pena, Katharina Wassilew, Michael Perch, Sandrine Hirschi, Marie-Pierre Chenard, Rebecca A. Sosa, Martin Goddard, Desley Neil, Angeles Montero-Fernandez, Alexandra Rice, Emanuele Cozzi, Federico Rea, Deborah J Levine, Antoine Roux, Fiorella Calabrese
Background Pulmonary antibody-mediated rejection is still a challenging diagnosis as C4d has poor sensitivity. Previous studies have indicated that the phosphorylated S6 ribosomal protein, a component of the mammalian target of rapamycin (mTOR) pathway, is correlated with de novo donor-specific antibodies in lung transplantation. The objective of this study was to evaluate the phosphorylation of S6
-
HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-05 Jiho Han, Josh Rushakoff, Yasbanoo Moayedi, Erik Henricksen, Roy Lee, RN Helen Luikart, Omar Shalakhti, Loren Gragert, Lillian Benck, Darren Malinoski, Jon Kobashigawa, Jeffrey Teuteberg, Kiran K. Khush, Jignesh Patel, Evan Kransdorf
Purpose Primary graft dysfunction (PGD) is a leading cause of early morbidity and mortality following heart transplantation (HT). Human leukocyte antigen (HLA) sensitization increases the risk of rejection and adverse outcomes after HT. We sought to determine the association between pre-transplant HLA sensitization, as measured using the calculated panel reactive antibody (cPRA) value, and the risk
-
So, it’s gonna be forever, or it’s gonna go down in flames: LVAD patient-reported outcomes ….no longer a Blank Space! J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-04 Thomas M. Cascino, Manreet K. Kanwar
Abstract not available
-
Mollicutes-related infections in thoracic surgery including lung and heart transplantation: a systematic review. J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-03 Eric Farfour, Marc Vasse, Alexandre Vallée
Background Urogenital Mollicutes, i.e., Mycoplasma hominis and Ureaplasma spp., can colonize the urogenital tract. While urogenital colonization is frequent, infections are rare but should not be missed. Furthermore, extragenital infections are even rarer. Over the past years, they have been increasingly documented as a cause of hyperammonemia syndrome (HS) and post-surgical infections. We review the
-
IgM Marks Persistent IgG Anti-Human Leukocyte Antigen Antibodies in Highly Sensitized Heart Transplant Patients J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-02 Fang Li, Loren Gragert, D. Giovanni Biagini, Jignesh K Patel, Jon A. Kobashigawa, Johannes Trück, Oscar Rodriguez, Corey T Watson, David Gibb, Xiaohai Zhang, Evan P Kransdorf
Background Sensitization to human leukocyte antigens (HLA) is a persistent problem in heart transplant (HT) candidates. We sought to characterize the anti-HLA antibody and circulating B cell repertoire in a cohort of highly sensitized HT candidates. Methods We assessed IgG and IgM anti-HLA antibodies using luminex single antigen bead assays in a cohort of 11 highly sensitized (HS; calculated panel
-
A Multi-omic and Multi-Species Analysis of Right Ventricular Dysfunction J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-10-01 Jenna B. Mendelson, Jacob D. Sternbach, Michelle J. Doyle, Lauren Mills, Lynn M. Hartweck, Walt Tollison, John P. Carney, Matthew T. Lahti, Richard W. Bianco, Rajat Kalra, Felipe Kazmirczak, Charles Hindmarch, Stephen L Archer, Kurt W. Prins, Cindy M. Martin
Background Right ventricular failure (RVF) is a leading cause of morbidity and mortality in multiple cardiovascular diseases, but there are no approved treatments for RVF as therapeutic targets are not clearly defined. Contemporary transcriptomic/proteomic evaluations of RVF are predominately conducted in small animal studies, and data from large animal models are sparse. Moreover, a comparison of
-
Robotic-Assisted Lung Transplantation: First in Man J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-29 Dominic Emerson, Pedro Catarino, Reinaldo Rampolla, Joanna Chikwe, Dominick Megna
Lung transplantation remains the best option for patients with end-stage lung disease.However, this operation has historically carried significant potential morbidity. To improve near-term patient outcomes, attempts have been made to decrease invasiveness, but this is limited by the complex nature of the operation and the anatomy of the chest. To facilitate further reduction in incision size and augment
-
CT-based Machine Learning for Donor Lung Screening Prior to Transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-29 Sundaresh Ram, Stijn E Verleden, Madhav Kumar, Alexander J. Bell, Ravi Pal, Sofie Ordies, Arno Vanstapel, Adriana Dubbeldam, Robin Vos, Stefanie Galban, Laurens J. Ceulemans, Anna E. Frick, Dirk E. Van Raemdonck, Johny Verschakelen, Bart M. Vanaudenaerde, Geert M. Verleden, Vibha N Lama, Arne P. Neyrinck, Craig J. Galban
Background Assessment and selection of donor lungs remains largely subjective, and experience based. Criteria to accept or decline lungs are poorly standardized and are not compliant with the current donor pool. Using ex vivo CT images, we investigated the use of a CT-based machine learning algorithm for screening donor lungs prior to transplantation. Methods Clinical measures and ex-situ CT scans
-
Non-Inferior Outcomes in Lower Urgency Patients Transplanted with Extended Criteria Donor Hearts J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-29 Max Shin, Amit Iyengar, Mark R. Helmers, Cindy Song, David Rekhtman, John J. Kelly, Noah Weingarten, William L. Patrick, Marisa Cevasco
Introduction Recent work has suggested that outcomes among heart transplant patients listed at the lower-urgency (United Network for Organ Sharing Status 4 or 6) status may not be significantly impacted by donor comorbidities. The purpose of this study was to investigate outcomes of extended criteria donors (ECD) in lower vs. higher urgency patients undergoing heart transplantation. Methods The United
-
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-29 Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, Anna R. Hemnes, Murali M. Chakinala, Kelly M. Chin, Michelle Han, Michelle Cho, Tobore Tobore, Mohammad Rahman, Nick H. Kim
Background Selexipag is an oral prostacyclin receptor agonist, indicated for pulmonary arterial hypertension to delay disease progression and reduce the risk of pulmonary arterial hypertension-related hospitalization. SelexiPag: tHe usErs dRug rEgistry (NCT03278002) was a US-based, prospective, real-world registry of selexipag-treated patients. Methods Adults with pulmonary hypertension (enrolled 2016-2020)
-
Changing Patterns in Lung Transplant for Respiratory Failure Due to COVID-19 in the U.S. J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-26 Kemarut Laothamatas, Luke Benvenuto, Frank D’Ovidio, Selim M. Arcasoy
Many patients with severe COVID-19 have been affected by acute respiratory distress syndrome, which has been associated with increased mortality, and up to 31% of these survivors had persistent interstitial lung abnormalities with impaired lung function and quality of life even after 6 to 24 months after initial disease. Lung transplantation quickly emerged as a viable therapy for select patients with
-
-
HeartMate 3 Snoopy: Non-invasive cardiovascular diagnosis of patients with fully magnetically levitated blood pumps during echocardiographic speed ramp tests and Valsalva maneuvers J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-26 T. Schlöglhofer, C. Gross, T. Abart, AK. Schaefer, C. Marko, M. Röhrich, G. Widhalm, F. Kaufmann, I. Weigel, H. Al Asadi, B. Karner, J. Riebandt, D. Wiedemann, G. Laufer, H. Schima, D. Zimpfer
-
-
Information for Readers J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-22
Abstract not available
-
Relationship Between Blood and Tissue-Based Rejection-Related Transcripts in Heart Transplantation J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-18 Dae Hyun Lee, Ahsan Usmani, Vani Ravichandran, Tammi Wicks, Robby Wu, Theresa Wolf-Doty, Ioana Dumitru, Peter Berman, Guilherme H. Oliveira, Benjamin Mackie
Purpose The purpose of the study is to investigate the relationship between blood and tissue-derived rejection-related transcripts from blood gene expression profiling (GEP) and molecular microscope in the setting of allograft rejection in heart transplant. Methods All heart transplant patients from August 2021 to May 2022 with both circulating blood GEP (AlloMap; CareDx) and endomyocardial biopsy
-
Aortic Root Thrombosis in Patients with HeartMate 3 Left Ventricular Assist Device Support J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-20 Matthew R. Carey, Dylan Marshall, Kevin Clerkin, Ronald Laracuente, Joseph Sanchez, Sneha S. Jain, Jayant K. Raikhelkar, Jay S. Leb, Yuji Kaku, Melana Yuzefpolskaya, Yoshifumi Naka, Paolo C. Colombo, Gabriel T. Sayer, Koji Takeda, Nir Uriel, Veli K. Topkara, Justin A. Fried
Background Aortic root thrombus (ART) formation is a complication of continuous flow left ventricular assist device (LVAD) therapy. However, the incidence and related complications of ART in HeartMate 3 (HM3) patients remains unknown. Methods Patients who underwent HM3 implantation from November 2014 through August 2020 at a quaternary academic medical center were included. Demographics and outcomes
-
Perioperative Extracorporeal Membrane Oxygenation Support for Pulmonary Endarterectomy: A 17-year Experience from the UK National Cohort J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-18 Alicia X.F. CHIA, Kamen VALCHANOV, Choo NG, Steven TSUI, John TAGHAVI, Alain VUYLSTEKE, Jo-anne FOWLES, David P. JENKINS
Background Pulmonary endarterectomy(PEA) is the guideline recommended treatment for patients with chronic thromboembolic pulmonary hypertension(CTEPH). However, some patients develop severe cardiopulmonary compromise either prior to surgery, intraoperatively or early postoperatively. This may result from advanced CTEPH, reperfusion pulmonary oedema, massive endobronchial bleeding or right ventricular(RV)
-
Acute Rejection In Donation After Circulatory Death (DCD) Heart Transplants J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-17 Selena S. Li, Masaki Funamoto, Asishana A. Osho, Seyed A. Rabi, Dane Paneitz, Ruby Singh, Eriberto Michel, Gregory D. Lewis, David A. D’Alessandro
Background Donation after circulatory death (DCD) heart transplantation has promising early survival, but effects on rejection remain unclear. Methods The United Network for Organ Sharing (UNOS) database was queried for adult heart transplants from 12/01/2019 to 12/31/2021. Multiorgan transplants and loss to follow-up were excluded. Primary outcome was acute rejection, comparing DCD and donation after
-
COVID-19 outcomes in heart transplant recipients: a large Australian cohort. J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-14 C Cherrett, J Cao, C Adams, PS Macdonald
Heart transplant recipients have been reported to be at a significantly elevated risk of poor outcomes from COVID-19 infection owing to their underlying comorbidities and immunosuppression. We conducted a single-centre retrospective cohort of all heart transplant recipients who were known to have contracted COVID-19 between January 2020 to September 2022. Electronic medical records were used to collect
-
Cardiac Allograft Vasculopathy and Survival in Pediatric Heart Transplant Recipients Transitioned to Adult Care J. Heart Lung Transplant. (IF 8.9) Pub Date : 2023-09-11 Eduard Rodenas-Alesina, Natasha Aleksova, Michael Stubbs, Farid Foroutan, Stella Kozuszko, Juan Duero Posada, Michael McDonald, Yasbanoo Moayedi, Heather Ross, Anne Dipchand
Background Cardiac allograft vasculopathy (CAV) is an important cause of mortality after pediatric heart transplantation (HT) but there is a paucity of data regarding its incidence and impact on survival in pediatric recipients transitioned to adult care. Methods We conducted a retrospective review of consecutive pediatric HT patients from 1989-2017 at the Hospital for Sick Children who transitioned